新药时代自体造血干细胞移植治疗多发性骨髓瘤的地位
Status of autologous hematopoietic stem cell transplantation in the treatment of multiple myeloma in the new drug era
摘要
自上世纪80年代开始，由于采用自体造血干细胞移植（ASCT）治疗年轻的（年龄〈65岁）有症状的多发性骨髓瘤（MM），显著改善了年轻MM患者的长期生存率。因而，ASCT已经成为初治年轻MM患者的标准治疗方法。在过去的10年里，
出处
《临床血液学杂志》
CAS
2015年第5期753-756,共4页
Journal of Clinical Hematology
关键词
多发性骨髓瘤
自体造血干细胞移植
multiple myeloma
autologous hematopoietic stem cell transplantation
参考文献28
-
1Cavo M,Rajkumar SV,Palumbo A,et al.International Myeloma Working Group.International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation[J].Blood,2011,117:6063-6073.
-
2Moreau P,Avet-Loiseau H,Harousseau JL,et al.Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies[J].J Clin Oncol,2011,29:1898-1906.
-
3Palumbo A,Rajkumar SV,San Miguel JF,et al.International Myeloma Working Group consensus statement for the management,treatment,and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation[J].J Clin Oncol,2014,32:587-600.
-
4Harousseau JL,Attal M,Avet-Loiseau H,et al.Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stemcell transplantation in newly diagnosed multiple myeloma:results of the IFM 2005-01phase III trial[J].J Clin Oncol,2010,28:4621-4629.
-
5Cavo M,Tacchetti P,Patriarca F,et al.GIMEMA Italian Myeloma Network.Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before,and consolidation therapy after,double autologous stemcell transplantation in newly diagnosed multiple myeloma:a randomized phase 3study[J].Lancet,2010,376:2075-2085.
-
6Moreau P,Avet-Loiseau H,Facon T,et al.Bortezomib plus dexamethasone versus reduced-dose bortezomib,thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma[J].Blood,2011,118:5752-5758,quiz 5982.
-
7Rosiol L,Oriol A,Teruel AI,et al.Superiority of bortezomib,thalidomide,and dexamethasone(VTD)as induction pretransplantation therapy in multiple myeloma:a randomized phase 3 PETHEMA/GEM study[J].Blood,2012,120:1589-1596.
-
8Moreau P,Facon T,Attal M,et al.Comparison of 200mg/m(2)melphalan and 8Gy total body irradiation plus 140 mg/m(2)melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma:final analysis of the Intergroupe Francophone du Myélome9502randomized trial[J].Blood,2002,99:731-735.
-
9Bayraktar UD,Bashir Q,Qazilbash M,et al.Fifty years of melphalan use in hematopoietic stem cell transplantation[J].Biol Blood Marrow Transplant,2013,19:344-356.
-
10Roussel M,Moreau P,Huynh A,et al.Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma:aphase 2study of the Intergroupe Francophone du Myelome(IFM)[J].Blood,2010,115:32-37.
-
1达万明.恶性淋巴瘤的自体造血干细胞移植治疗现状[J].解放军医学杂志,1997,22(5):379-381. 被引量：1
-
2曹红花,何明生.自体造血干细胞移植联合大剂量化疗治疗卵巢癌[J].国际内科学杂志,2007,34(8):486-488. 被引量：1
-
3钟美佐,陈方平,齐振华,唐果成,张国萍,皮海珍,欧阳红斌.自体造血干细胞移植治疗恶性血液病[J].中国现代医学杂志,1999,9(8):32-32. 被引量：4
-
4张茂宏,孙恺.自体造血干细胞移植治疗多发性骨髓瘤的研究进展[J].中华血液学杂志,1998,19(6):331-333. 被引量：8
-
5侯健,樊建玲.新药时代自体造血干细胞移植在多发性骨髓瘤中的应用前景[J].中国肿瘤临床,2015,42(1):8-12. 被引量：7
-
6于式翠,仇兆丰.自体造血干细胞移植治疗非霍奇金淋巴瘤7例护理[J].中国乡村医药,2008,15(3):77-78.
-
7陈芳,朱林林.多发性骨髓瘤患者自体造血干细胞移植的护理[J].中华现代护理杂志,2016,22(36):5284-5285. 被引量：7
-
8李勇华,侯健,王东星,傅卫军,袁振刚,陈玉宝,奚昊.自体造血干细胞移植对多发性骨髓瘤患者预后的影响[J].中华血液学杂志,2008,29(4):222-225.
-
9易树华,刘薇,吕瑞,李增军,徐燕,隋伟薇,黄文阳,王婷玉,邓书会,刘宏,傅明伟,邹德慧,邱录贵.增强剂量免疫化疗联合或不联合自体造血干细胞移植治疗29例初治年轻中高危/高危弥漫大B细胞淋巴瘤[J].中华血液学杂志,2014,35(6):546-550. 被引量：7
-
10崔秀珍,郝希山,李树玲.自体造血干细胞移植治疗乳腺癌现状[J].中国肿瘤临床,1999,26(10):788-791.
